^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BCMA targeted CAR T-cells
i
Other names: BCMA targeted CAR T-cells, BCMA-targeted CAR-T cells therapy, humanized BCMA-targeted CAR-T cells therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shanghai Yake Biotech
Drug class:
BCMA-targeted CAR-T immunotherapy
Related drugs:
over1year
HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy. (PubMed, Bone Marrow Transplant)
Of 4 patients with HBV reactivation, 2 cases (50%) of severe hepatitis were noted and reported. Drops of serum IgG and elevation of alanine aminotransferase (ALT), alanine aminotransferase (AST), total bilirubin (TB) were observed in all four patients around the date of HBV reactivation.
Retrospective data • Journal • CAR T-Cell Therapy
|
BCMA targeted CAR T-cells
over1year
Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma. (PubMed, Front Immunol)
Patients (n=105) with r/r MM treated with BCMA-targeted CAR-T cell therapy were included...TLS is a frequently observed CAR-T therapy complication and negatively influences clinical response and prognosis. Close monitoring for TLS should be implemented during CAR-T cell therapy, especially for those at high TLS risk.
Journal • CAR T-Cell Therapy
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CRP (C-reactive protein)
|
BCMA targeted CAR T-cells
4years
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies (clinicaltrials.gov)
P1, N=120, Recruiting, Zhejiang University
Clinical • New P1 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
dasatinib • BCMA targeted CAR T-cells • CD19/BCMA targeted CAR T-cells
Share via
